About: The smoker's paradox after successful fibrinolysis: reduced risk of reocclusion but no improved long-term cardiac outcome

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The smoker's paradox after successful fibrinolysis: reduced risk of reocclusion but no improved long-term cardiac outcome Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 26 June 2008

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в червні 2008 (uk) im Juni 2008 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 26 June 2008 (en) artículu científicu espublizáu en xunu de 2008 (ast) գիտական հոդված հրատարակված 2008 թվականի հունիսի 26-ին (hy)
publication date	wds:Q81526888-13C8DEE2-43C6-4103-9D4A-0B5B2E427CA8
publication date	2008-06-26 00:00:00Z (xsd:dateTime)
exact match	wds:Q81526888-B3B38F00-3B67-481B-B160-E3669795FB14
exact match	https://scigraph.springernature.com/pub.10.1007/s11239-008-0238-6
cites work	wds:Q81526888-0B449770-2FCB-4B11-AC2D-4E6BE08E5909 wds:Q81526888-1DAA7CE1-B307-46C6-BC23-9361CD339DB7 wds:Q81526888-1E9A8897-15D4-4B68-9098-4BBB85F524CD wds:Q81526888-297A5F18-BAEB-4886-AF7E-E77DC20988C3 wds:Q81526888-2D44FB66-1F29-4E6C-B2F7-02A2B099E7B8 wds:Q81526888-306A4B92-E2B7-4EDA-B45E-94BD93B38542 wds:Q81526888-3EB2F3B2-8D12-47CE-9B84-0ADC8CC9AC88 wds:Q81526888-4A9898F3-D61B-4E80-978E-73BB681F7072 wds:Q81526888-4DD5D18A-C149-4E14-9A04-422E8C099E9A wds:Q81526888-4F2CC092-2AA8-46E5-84CB-EBF5D339747D wds:Q81526888-50B4E5A7-1032-4DE0-B9CD-C25CEAB66F32 wds:Q81526888-50CB7B4B-B832-4587-9DC8-F636E760A51C wds:Q81526888-5A4CB422-D5EB-485E-B8A0-B7633168A7CA wds:Q81526888-67521E7C-77FA-4EE3-BAB5-C51024533E1F wds:Q81526888-67FE0E5C-654E-4573-BF5B-76252D6CD4FD wds:Q81526888-71AF3A63-D852-4E01-93C8-A234DABC7844 wds:Q81526888-75477D26-2ABF-472B-ADF2-01BD4857268D wds:Q81526888-819A0855-1BE1-43C7-BB7B-9BF8710D1241 wds:Q81526888-936B3012-7C81-4ECB-B8C1-319E4D9B10A3 wds:Q81526888-955A98B7-67CE-4ED9-9BFB-06315F5837BB wds:Q81526888-95B29131-28F7-44AD-B4B6-91058047D78A wds:Q81526888-A59D5AA6-4474-4125-BE81-BCEC94C6566A wds:Q81526888-AEADF985-DB20-44A7-A365-A31082762495 wds:Q81526888-B1B462A9-C1A2-4959-B011-D05926B1DCB3 wds:Q81526888-B4A042C0-D0F6-4E92-A095-A0B5F868576C wds:Q81526888-BC3F1F8A-04CE-47C5-9836-875040215ADF wds:Q81526888-BE3DD8B4-1A02-40DA-BCC9-2B4896735697 wds:Q81526888-C288A77E-FA4E-412C-B566-2C7E693D7DC0 wds:Q81526888-CF4AC4DD-AA9E-4775-90F9-40CC716F3DB1 wds:Q81526888-D13AB218-B7B4-43A9-AA51-315575761B40 wds:Q81526888-D21D0C20-2639-4E28-B2F5-D0055D2C2FEB wds:Q81526888-D2AE770A-25CA-404D-B3B9-C9E79FC29718 wds:Q81526888-D2CAB141-D25C-4654-AEF1-EC84747FDBDC wds:Q81526888-DF6F9B32-2ED6-49C5-B241-A136CDB0773F wds:Q81526888-EC80B195-06D0-4ABC-8626-33A9756E32D2 wds:Q81526888-FF3E1771-7198-4C37-8072-00D6F9322CD7
cites work	Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study. Results of the APRICOT Study Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial Coronary angiographic morphology in myocardial infarction: a link between the pathogenesis of unstable angina and myocardial infarction. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2 An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators Mortality in relation to smoking: 40 years' observations on male British doctors A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial Left ventricular function at 3 months after successful thrombolysis. Impact of reocclusion without reinfarction on ejection fraction, regional function, and remodeling How do smokers differ from nonsmokers in their response to thrombolysis? (the TIMI-4 trial) Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction. Experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction. Analyses of patient subgroups in the Thrombolysis in Myocardial Infarction (TIMI) trial, phase II TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation : An Intravenous nPA for Treatment of Infarcting Myocardium Early II Trial Substudy Update on the role of cigarette smoking in coronary artery disease Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group Reocclusion: the flip side of coronary thrombolysis Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the "smoker's paradox" from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptoki Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction--the smoker's paradox revisited. Culprit lesion morphology and stenosis severity in the prediction of reocclusion after coronary thrombolysis: angiographic results of the APRICOT study. Antithrombotics in the Prevention of Reocclusion in Coronary Thrombolysis Accuracy and precision of quantitative digital coronary arteriography: observer-, short-, and medium-term variabilities Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. Sustained coronary patency after fibrinolytic therapy as independent predictor of 10-year cardiac survival Observations from the Antithrombotics in the Prevention of Reocclusion in COronary Thrombolysis (APRICOT) trial Abnormal coronary flow in infarct arteries 1 year after myocardial infarction is predicted at 4 weeks by corrected Thrombolysis in Myocardial Infarction (TIMI) frame count and stenosis severity Effect of cigarette smoking on coronary patency after thrombolytic therapy for myocardial infarction. TEAM-2 Investigators. Second Multicenter Thrombolytic Trials of Eminase in Acute Myocardial Infarction Adverse long-term effects of reocclusion after coronary thrombolysis The smoker's paradox: insights from the angiographic substudies of the TIMI trials. Comparison of mortality rates after acute myocardial infarction in smokers versus nonsmokers Clinical predictors of early infarct-related artery patency following thrombolytic therapy: importance of body weight, smoking history, infarct-related artery and choice of thrombolytic regimen: the GUSTO-I experience. Global Utilization of Streptok Percutaneous coronary intervention after fibrinolysis: a multiple meta-analyses approach according to the type of strategy High-grade infarct-related stenosis after successful thrombolysis: strong predictor of reocclusion, but not of clinical reinfarction
author name string	wds:Q81526888-2264676E-B6D2-4E5C-AA5E-D67158145C95 wds:Q81526888-27726602-389B-448C-BA9B-C4E5A1EF8DD4 wds:Q81526888-71F52A72-2608-4259-9D71-9670BEE56A88 wds:Q81526888-829CD457-2F30-4267-954A-16F400EAD6D4 wds:Q81526888-D7EACC71-5C80-4328-97C6-807ED8DA10B6
author name string	Freek W A Verheugt Marc A Brouwer Gerrit Veen Peter C Kievit Wim R M Aengevaeren
rdfs:label	The smoker's paradox after successful fibrinolysis: reduced risk of reocclusion but no improved long-term cardiac outcome (en) The smoker's paradox after successful fibrinolysis: reduced risk of reocclusion but no improved long-term cardiac outcome (nl)
skos:prefLabel	The smoker's paradox after successful fibrinolysis: reduced risk of reocclusion but no improved long-term cardiac outcome (en) The smoker's paradox after successful fibrinolysis: reduced risk of reocclusion but no improved long-term cardiac outcome (nl)
name	The smoker's paradox after successful fibrinolysis: reduced risk of reocclusion but no improved long-term cardiac outcome (en) The smoker's paradox after successful fibrinolysis: reduced risk of reocclusion but no improved long-term cardiac outcome (nl)
title	wds:Q81526888-AD80E56B-B03B-431B-8F71-739DCDCB64A8

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 195 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software